EXEL logo

Exelixis Inc. (EXEL)

$68.50

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on EXEL

Market cap

$16.71B

EPS

3.35

P/E ratio

18.7

Price to sales

6.09

Dividend yield

--

Beta

0.454266

Price on EXEL

Previous close

$67.10

Today's open

$66.75

Day's range

$66.26 - $68.54

52 week range

$39.71 - $73.69

Profile about EXEL

CEO

Michael M. Morrissey

Employees

1077

Headquarters

Alameda, CA

Exchange

Nasdaq Global Select

Shares outstanding

244010895

Issue type

Common Stock

EXEL industries and sectors

Healthcare

Biotechnology & Life Sciences

News on EXEL

Exelixis, Inc. (EXEL) Presents at UBS Global Biopharma Conference 2026 Transcript

Exelixis, Inc. (EXEL) Presents at UBS Global Biopharma Conference 2026 Transcript

news source

Seeking Alpha • Nov 17, 2026

news preview

Where Will Exelixis Be in 5 Years? 1 Experimental Drug Could Change Everything

Cabometyx's sales keep growing, but generic competition looms by the end of the decade. Meanwhile, zanzalintinib could earn approval by March of 2027.

news source

The Motley Fool • Nov 16, 2026

news preview

Exelixis Has 2 Major Catalysts Coming by March 2027. Here's What Investors Should Watch.

Exelixis' cabozantinib, addressing various types of cancer, has driven tremendous growth over the past 10 years. The company is now betting on a next-generation candidate that's approaching the finish line.

news source

The Motley Fool • Nov 13, 2026

news preview

Exelixis Bets on Zanza as Next Cancer Franchise as FDA Decision Nears

Exelixis NASDAQ: EXEL is working to build its next cancer drug franchise around zanzalintinib, or zanza, while continuing to grow its established CABO business, Chief Strategy Officer Andrew Peters said at a conference discussion with Guggenheim biotech analyst Michael Schmidt.

news source

MarketBeat • Nov 11, 2026

news preview

Exelixis Nears FDA Decision, Key Kidney Cancer Data for Zanzalintinib

Exelixis NASDAQ: EXEL is preparing for a regulatory decision on its cancer drug candidate zanzalintinib and expects results from a kidney cancer study in the first quarter of next year, Chief Strategy Officer Andrew Peters said at an investor event.

news source

MarketBeat • Nov 11, 2026

news preview

Exelixis, Inc. (EXEL) Presents at Stifel 2026 Healthcare Conference 2026 Transcript

Exelixis, Inc. (EXEL) Presents at Stifel 2026 Healthcare Conference 2026 Transcript

news source

Seeking Alpha • Nov 11, 2026

news preview

Exelixis, Inc. (EXEL) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript

Exelixis, Inc. (EXEL) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript

news source

Seeking Alpha • Nov 10, 2026

news preview

Here's Why Exelixis (EXEL) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

news source

Zacks Investment Research • Nov 9, 2026

news preview

The Top 5 Biotech Stocks I'd Buy Right Now Without Any Hesitation

These five biotechs all have promising late-stage pipeline candidates. Existing products and new launches could power strong returns for all five over the medium term.

news source

The Motley Fool • Nov 8, 2026

news preview

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in November:Guggenheim 3rd Annual Healthcare Innovation Conference: Exelixis is scheduled to present at 9:30 a.m. ET / 6:30 a.m. PT on Tuesday, November 10 in Boston.Stifel 2026 Healthcare Conference: Exelixis is scheduled to present at 1:20 p.m. ET / 10:20 a.m. PT on Wednesday, November 11 in New York City.UBS Global Bio.

news source

Business Wire • Nov 3, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Exelixis Inc.

Open an M1 investment account to buy and sell Exelixis Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in EXEL on M1